Dyne Therapeutics, Inc. (DYN) stock
Close on Nov 11, 2026Market cap $3.36BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $3.36B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.61
- Dividend yield
- –
- Free cash flow yield
- -16.93%
Fundamentals
- Net income
- -$604.92M
- EPS, diluted
- -$3.47
- Free cash flow
- -$568.76M
Trading
- Next earnings
- Mar 1, 2027 (estimated, before the open)
- Previous close
- $17.92
- Open
- $18.10
- Day's range
- $17.84 – $18.31
- Volume
- 1,909,775
- Average volume (20 days)
- 2,528,050
- Index membership
- Russell 2000 (since Dec 2020), Russell 3000 (since Feb 2021)
- Beta (5 years)
- 1.38
- 52-week range
- $14.00 – $27.30
- RSI (14 days)
- 55.3
- Volatility (1 year)
- 64.1%
- Relative volume
- 0.69×
- WACC
- 11.8%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | DYN | S&P 500 | Difference | DYN per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +8.1% | -2.4% | +10.5 pts | ||
| 3 months | -32.6% | -1.2% | −31.5 pts | ||
| Year to date | -8.0% | +12.3% | −20.3 pts | ||
| 1 year | -8.5% | +12.4% | −21.0 pts | ||
| 3 years | +106.8% | +78.8% | +28.0 pts | +27.4% | +21.4% |
| 5 years | +26.6% | +75.2% | −48.6 pts | +4.8% | +11.9% |
| 10 years | +116.0% | +311.1% | −195.1 pts | +8.0% | +15.2% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Dyne Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Update
- Results
- News
- Update
About Dyne Therapeutics
Pharmaceutical Preparations
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company that develops targeted therapeutics for individuals affected by genetically driven neuromuscular disorders. Utilizing its proprietary FORCE platform, the company conjugates transferrin receptor 1-binding antibody fragments with molecular payloads, including oligonucleotides and enzymes, to deliver therapies directly to muscle tissues and the central nervous system. Its primary pipeline candidates include zeleciment rostudirsen, which addresses Duchenne muscular dystrophy amenable to exon 51 skipping, and zeleciment basivarsen, aimed at treating myotonic dystrophy type 1. Dyne also advances programs targeting facioscapulohumeral dystrophy and Pompe disease, serving patient populations living with these severe genetic conditions.
Company profile, executives and historyDyne Therapeutics stock: common questions
What is Dyne Therapeutics's stock price?
DYN closed at $17.99 on Nov 11, 2026, up 0.39% on the day. Over the past 52 weeks it traded between $14.00 and $27.30.
What is Dyne Therapeutics's market cap?
Dyne Therapeutics was worth $3.36B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is DYN's P/E ratio?
Dyne Therapeutics lost money over fiscal 2025 (diluted EPS -$3.47), so it has no meaningful P/E ratio.
Does Dyne Therapeutics pay a dividend?
No. Dyne Therapeutics has not paid a cash dividend over the last twelve months.
When does Dyne Therapeutics report earnings next?
Dyne Therapeutics is expected to report Q4 FY2026 results on Mar 1, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has DYN stock performed over the past year?
Including dividends, DYN returned -8.5% over the past year, against +12.4% for the S&P 500.
How many DYN shares are sold short?
24M shares were sold short at the latest FINRA report, 13.79% of the float, or 10.8 days of average trading volume.
Who are Dyne Therapeutics's competitors?
Companies most similar to Dyne Therapeutics by business, industry and size include PEPG, TRDA, WVE, DSGN, SRPT.
See a number that looks wrong?